Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1997-5-27
pubmed:abstractText
Experiments were conducted to test the hypothesis that estrogen treatment will regress a persistent dominant follicle developed during melengestrol acetate (MGA) treatment in the absence of a functional corpus luteum (CL) with normal fertility following development and ovulation of a newly recruited follicle. In Exp. 1, nonlactating beef cows (n = 31) were administered .5 mg.cow-1.d-1 of MGA (d 0) for 14 d with 25 mg of prostaglandin F2 alpha (PGF2 alpha) administered on d 6 and 8 to regress the CL. On d 11 of treatment, approximately half the MGA-treated cows received 5 mg of estradiol valerate (EV) i.m. (MGAEV, n = 14) and the remainder were maintained on MGA (n = 17). Ovaries were checked with ultrasound on d 8, 10, 12, and 14 of MGA treatment and every day until ovulation. A persistent dominant follicle developed in 90% of the MGA-treated cows by d 10 of treatment. Most of the MGA-treated cows ovulated the persistent dominant follicle (n = 13/17), whereas EV treatment regressed the persistent dominant follicle (n = 10/14) with the recruitment of a new follicle that ovulated (n = 8/10). Diameter of the ovulatory follicle was larger (P < .05) for the MGA (19.8 +/- .6 mm) than for the control (15.1 +/- .8 mm) and MGAEV (14.8 +/- .7 mm) cows. In Exp. 2, nonlactating, multiparous beef cows (n = 97) and yearling heifers (n = 38) were equally allotted to either a control, MGA alone, or MGA + estradiol-17 beta (MGAE) group with the same dose of MGA as administered in Exp. 1. The 1st d of MGA feeding was the 1st d of treatment. On d 10 of treatment half the MGA-treated animals were injected i.m. with 5 mg of estradiol-17 beta. In controls, behavioral estrus was detected and animals were artificially inseminated (AI) for 5 d (d 10 to 14 of experiment). All controls not exhibiting estrus by d 15 of experiment were injected with 25 mg of PGF2 alpha. The remaining controls and all MGA cows were observed for behavioral estrus and AI commenced for 7 d following withdrawal of MGA (d 15 to 21 of experiment). More (P < .05) controls (90.3%) than MGA (84.8%) or MGAE (63.6%) cows showed estrus within 7 d after MGA withdrawal. The percentage of animals conceiving to the synchronized estrus did not differ (P > .05) among treatments. The data support our hypothesis that a persistent dominant follicle developed and can be regressed with exogenous estrogen treatment followed by the recruitment and ovulation of a new follicle after MGA withdrawal and fertility of that estrus does not seem to be significantly compromised.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0021-8812
pubmed:author
pubmed:issnType
Print
pubmed:volume
75
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
745-54
pubmed:dateRevised
2003-11-14
pubmed:meshHeading
pubmed-meshheading:9078492-Animals, pubmed-meshheading:9078492-Cattle, pubmed-meshheading:9078492-Dinoprost, pubmed-meshheading:9078492-Drug Synergism, pubmed-meshheading:9078492-Estradiol, pubmed-meshheading:9078492-Estrogens, pubmed-meshheading:9078492-Estrus, pubmed-meshheading:9078492-Estrus Synchronization, pubmed-meshheading:9078492-Female, pubmed-meshheading:9078492-Luteolysis, pubmed-meshheading:9078492-Melengestrol Acetate, pubmed-meshheading:9078492-Ovarian Follicle, pubmed-meshheading:9078492-Ovary, pubmed-meshheading:9078492-Ovulation, pubmed-meshheading:9078492-Pregnancy, pubmed-meshheading:9078492-Pregnancy Rate, pubmed-meshheading:9078492-Progesterone, pubmed-meshheading:9078492-Progesterone Congeners, pubmed-meshheading:9078492-Random Allocation, pubmed-meshheading:9078492-Time Factors
pubmed:year
1997
pubmed:articleTitle
Persistence of the dominant follicle during melengestrol acetate administration and its regression by exogenous estrogen treatment in beef cattle.
pubmed:affiliation
Department of Animal Science, Oklahoma State University, Stillwater 74078-0425, USA.
pubmed:publicationType
Journal Article